LONDON--(BUSINESS WIRE)--Jul 10, 2019--
Vendors in the cancer biologics market have significantly increased investments for the development of cancer treating biologic molecules. Consequently, several biologic molecules have been developed, and most of them are in the late stage of development. Targeted therapy, gene therapy, stem cell therapy, cancer vaccines, and antisense and RNAi therapy are some of the classes of innovative biologics. Thus, new drug approvals and the presence of a robust pipeline are expected to fuel the cancer biologics market growth during the forecast period. Furthermore, this industry research report also presents a competitive analysis of the market by product (monoclonal antibodies, vaccines, cell and gene therapy, and others) and geography (Asia, Europe, North America, and ROW).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190710005270/en/
Technavio has released a new market research report on the global cancer biologics market from 2019-2023. (Graphic: Business Wire)
Competitive vendor landscape
The global cancer biologics market is highly competitive with major vendors such as Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck & Co., Inc., competing based on price, quality, and market presence.
“The use of predictive biomarkers is increasing significantly as it helps physicians to decide treatments for their patients. Predictive biomarkers analyze the major etiological factors to study tumor growth in patients as the cancer etiology differs from patient to patient. Thus, the use of predictive biomarkers is increasing, which will fuel the growth of the cancer biologics market during the forecast period,” says a senior analyst at Technavio.
Top five cancer biologics market vendors
Amgen Inc. is one of the leading vendors in the human therapeutics segment, which focuses on the treatment of illness, primarily in the area of oncology, hematology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. The company offers various cancer therapies such as XGEVA, IMLYGIC, Vectibix, and BLINCYTO.
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company owns and operates biopharmaceuticals business, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sales of innovative medicines for the treatment of serious diseases. The company’s cancer biologics offerings include OPDIVO, EMPLICITI, and YERVOY.
Eli Lilly and Company
Eli Lilly and Company is one of the leading manufacturers of human pharmaceutical products and animal health products. Under its human pharmaceutical products segment, the company manufactures pharmaceutical products for endocrinology, oncology, cardiovascular, neuroscience, and immunology therapeutic areas and other areas globally. LARTRUVO, PORTRAZZA, ERBITUX, and CYRAMZA are some of the monoclonal antibodies offered by the company for the treatment of various cancers.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd owns and operates businesses in two segments, which include pharmaceuticals and diagnostics. The company offers various biologics for cancer treatment, including Herceptin, Avastin, MabThera/Rituxan, PERJETA, KADCYLA, TECENTRIQ, Herceptin Hylecta, and GAZYVA.
Merck & Co., Inc.
Merck & Co., Inc. manufactures and markets human health pharmaceuticals and vaccine products. Some of the company’s offerings in cancer biologics category are SYLATRON, ELSPA, KEYTRUDA, TICE BCG, INTRON, and GARDASIL.
Looking for more information on this market?Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
Global Non-small Cell Lung Cancer Drugs Market 2019-2023 - The market research study identifies AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck & Co., Inc., as the leading players in the global non-small cell lung cancer drugs market.
Global Laryngeal Cancer Therapeutics Market 2019-2023 - The market research study identifies Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Sanofi as the leading players in the global laryngeal cancer therapeutics market.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190710005270/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: STEM CELLS BIOTECHNOLOGY PHARMACEUTICAL ONCOLOGY HEALTH GENETICS
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 07/10/2019 05:30 AM/DISC: 07/10/2019 05:31 AM